

Investigations following increasing complaints about infusion sets for safe administration of cytostatics



E.Peyrilles, D.Frémont, G.Le Guyader, M.Perrinet, T.Storme, V.Massot Pharmacy Department, Robert Debré Hospital - 48, boulevard Sérurier - 75019 Paris. FRANCE



packaged in syringes.

OBJECTIVE

Identify risk factors that lead to CytoBolus

Adapter Set[®] malfunction, especially viscosity as

mentioned by the manufacturer.

Cumulative number of adverse events in time.

CONCLUSION & PERSPECTIVE

Viscosity does not appear to be the determining factor that leads to malfunction.

Further investigations would be necessary on both material and human factors.

MATERIAL AND METHODS

* Meeting nurses, pharmacists and CODAN representatives \rightarrow design of an Ishikawa diagram.

Carrying out a standard form to collect adverse events.

* Describing experimental design: influence of device, viscosity and infusion rate on delivered volume.

ADMINISTRATION DEVICES Three connectors	SOLUTIONS Three solutions	AUTOMATED INFUSION SYSTEM Orchestra® (FRESENIUS)	<u>Weighing</u> ➤ Volume estimates based on density of each solution	
Plain tube (VYGON)	Dextrose 10%		<u>Observations</u> ≻ Alarms	



CALCULATED VOLUMES: MEAN ± STANDARD DEVIATION (mL)

	Water		Dextrose 5%		Dextrose 10%	
Rate (mL/h)	1	50	1	50	1	50
Plain tube	19.99	49.79	19.90	50.03	19.83	49.97
	± 0.29	\pm 0.22	± 0.21	\pm 0.11	± 0.24	\pm 0.24
CytoBolus	19.72	50.04	19.74	49.85	19.58	49.80
Adapter Set®	± 0.25	\pm 0.25	± 0.15	\pm 0.39	± 1.04	\pm 0.20
PhaSeal®	19.21	49.80	19.82	49.51	19.77	50.16
	± 0.29	\pm 0.26	\pm 0.32	\pm 0.62	± 0.21	\pm 0.56

<u>At 1 ml/h</u> \rightarrow volumes delivered by the Phaseal[®] system unexpectedly lower with water for injection than dextrose 5% (p=0.00405) and dextrose 10% (p=0.00334).

→ Acceptable results, in compliance with the 3% accuracy of the automated infusion system (norm NF S 90-251).

* No leak, no defective devices for the 216 experiments.



20th EAHP Congress; 25-27 March 2014, Hamburg. Poster OHP-025